Menu Search
Equities

Panion & BF Biotech Inc

1760:TAI

Panion & BF Biotech Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (TWD)89.50
  • Today's Change0.20 / 0.22%
  • Shares traded68.52k
  • 1 Year change-19.73%
  • Beta--
Data delayed at least 20 minutes, as of Nov 22 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in TWDIncome statement in TWDView more

Year on year Panion & BF Biotech Inc's revenues fell -21.54% from 2.40bn to 1.88bn. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from 182.35m to 77.22m, a -57.65% decrease.
Gross margin52.43%
Net profit margin5.96%
Operating margin10.25%
Return on assets3.90%
Return on equity6.44%
Return on investment5.72%
More ▼

Cash flow in TWDView more

In 2023, Panion & BF Biotech Inc increased its cash reserves by 15.16%, or 70.37m. The company earned 177.42m from its operations for a Cash Flow Margin of 9.43%. In addition the company generated 48.67m cash from financing while 155.27m was spent on investing.
Cash flow per share3.39
Price/Cash flow per share26.30
Book value per share21.94
Tangible book value per share21.84
More ▼

Balance sheet in TWDView more

Panion & BF Biotech Inc has a Debt to Total Capital ratio of 27.17%, a higher figure than the previous year's 5.11%.
Current ratio1.42
Quick ratio0.8804
Total debt/total equity0.373
Total debt/total capital0.2717
More ▼

Growth rates in TWD

Year on year, both dividends per share and earnings per share excluding extraordinary items growth dropped -25.00% and -57.63%, respectively. Additionally when measured on a five year annualized basis, dividend per share growth is in-line with the industry average relative to its peers, while earnings per share growth is below the industry average.
Div yield(5 year avg)1.40%
Div growth rate (5 year)-3.23%
Payout ratio (TTM)106.00%
EPS growth(5 years)-15.14
EPS (TTM) vs
TTM 1 year ago		348.57
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.